COX-2 inhibition and prevention of cancer

被引:31
作者
Giercksky, KE [1 ]
机构
[1] Univ Oslo, Norwegian Radium Hosp, Dept Surg, Oslo, Norway
[2] Univ Oslo, Canc Res Inst, Oslo, Norway
关键词
COX-2; cyclo-oxygenase; NSAIDs; colorectal cancer; PPAR delta; angiogenesis; apoptosis; sulindac; APC; FAP;
D O I
10.1053/bega.2001.0237
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The potential for cyclo-oxygenase inhibition in cancer prevention and treatment is founded on epidemiology (reduction of colorectal cancer in aspirin users), animal experiments and molecular genetics. Trials using the NSAID sulindac also reduced the number of polyps in patients with familial adenomatous polyposis, but the well-known gastrointestinal toxic effects of aspirin and NSAIDs have discouraged the exploitation of their antineoplastic potential. The advent of specific COX-2 inhibitors, which do not interfere with the cytoprotective constitutive COX-1 enzyme, and the demonstration of increased COX-2 expression in many common malignancies beside colorectal cancer, has opened up new therapeutic possibilities. Recently a non-cyclo-oxygenase effect of COX-2 inhibitors, which combines the PPAR delta and the APC tumour suppressor activity, was also demonstrated. The selective COX-2 inhibitor celecoxib has been approved by the FDA for adjuvant treatment of familial adenomatous polyposis, and a large number of prevention and treatment trials of colorectal and other common cancers (prostate and breast cancer) have been started.
引用
收藏
页码:821 / 833
页数:13
相关论文
共 60 条
[11]   GENETIC IDENTIFICATION OF MOM-1, A MAJOR MODIFIER LOCUS AFFECTING MIN-INDUCED INTESTINAL NEOPLASIA IN THE MOUSE [J].
DIETRICH, WF ;
LANDER, ES ;
SMITH, JS ;
MOSER, AR ;
GOULD, KA ;
LUONGO, C ;
BORENSTEIN, N ;
DOVE, W .
CELL, 1993, 75 (04) :631-639
[12]   UP-REGULATION OF CYCLOOXYGENASE-2 GENE-EXPRESSION IN HUMAN COLORECTAL ADENOMAS AND ADENOCARCINOMAS [J].
EBERHART, CE ;
COFFEY, RJ ;
RADHIKA, A ;
GIARDIELLO, FM ;
FERRENBACH, S ;
DUBOIS, RN .
GASTROENTEROLOGY, 1994, 107 (04) :1183-1188
[13]  
Elder DJE, 1997, CLIN CANCER RES, V3, P1679
[14]   Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison [J].
Emery, P ;
Zeidler, H ;
Kvien, TK ;
Guslandi, M ;
Naudin, R ;
Stead, H ;
Verburg, KM ;
Isakson, PC ;
Hubbard, RC ;
Geis, GS .
LANCET, 1999, 354 (9196) :2106-2111
[15]   WHAT IS THE EVIDENCE THAT TUMORS ARE ANGIOGENESIS DEPENDENT [J].
FOLKMAN, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (01) :4-6
[16]   Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer [J].
Gupta, RA ;
Tan, J ;
Krause, WF ;
Geraci, MW ;
Willson, TM ;
Dey, SK ;
DuBois, RN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (24) :13275-13280
[17]   Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway [J].
Hanif, R ;
Pittas, A ;
Feng, Y ;
Koutsos, MI ;
Qiao, L ;
StaianoCoico, L ;
Shiff, SI ;
Rigas, B .
BIOCHEMICAL PHARMACOLOGY, 1996, 52 (02) :237-245
[18]  
Harris RE, 2000, CANCER RES, V60, P2101
[19]   COX-2 inhibitors [J].
Hawkey, CJ .
LANCET, 1999, 353 (9149) :307-314
[20]   Identification of c-MYC as a target of the APC pathway [J].
He, TC ;
Sparks, AB ;
Rago, C ;
Hermeking, H ;
Zawel, L ;
da Costa, LT ;
Morin, PJ ;
Vogelstein, B ;
Kinzler, KW .
SCIENCE, 1998, 281 (5382) :1509-1512